Rituximab as an effective add-on maintenance therapy for disease activities in childhood-onset systemic lupus erythematosus.

This study provides real-world data and illuminates rituximab's role in maintaining disease stability among patients with paediatric-onset SLE who are serologically active without major clinical deterioration. Most importantly, no mortality or development of end-stage renal disease was observed in the rituximab-treated cohort.